Medicaid Provider Alert: Provider revalidation has begun and those not completing the process risk disenrollment. Check your account now to learn when your revalidation is due. More information here.

Drugs and Therapeutics (D & T) Committee Drugs Under Review for: March 20, 2013

Drug Name	Review Type	Class	Manufacturer
Quillivant XR	New Drug Initial Review	Stimulants/ADHD	Pfizer
Xeljanz	New Drug Initial Review	Rheumatoid Arthritis	Pfizer
Aubagio	New Drug Initial Review	Multiple Sclerosis	Genzyme
Eliquis	New Drug Initial Review	Oral Anticoagulant	Bristol Myers-Squibb
Sklice	New Drug Initial Review	Pediculicide	Sanofi Pasteur
Gattex	New Drug Initial Review	GLP-2	NPS Pharmaceuticals
Oxtellar XR	New Drug Initial Review	Anticonvulsant	Supernus Pharmaceuticals
Tudorza Pressair	New Drug Initial Review	Long-acting Anticholingeric	Forest
Natroba	New Drug Appeal	Pediculicide	ParaPRO
Brilinta	PDL Appeal	Platelet Aggregation Inhibitor	AstraZeneca
Latuda	PDL Appeal	Atypical Antipsychotic	Sunovion

Footer